Under their collaborative agreement, MedinCell and Teva have selected a lead formulation for the longacting injectable mdc-ANG. Preclinical studies are expected to start this quarter.
mdc-ANG complements a range of antipsychotic products in development based on MedinCell’s
technology, including a first research product in clinical Phase 3 studies and another research product
in the late stages of preclinical development.